Doxycycline prophylaxis for STI prevention in women

This study from Kenya examined the emerging evidence around post-exposure prophylaxis (PEP) with doxycycline in cisgender women. Evidence already exists that doxycycline-PEP in cisgender men and transgender women can reduce sexually transmitted infections (STIs). Some 449 participants were randomised to 200 mg doxycycline post-condomless sex or standard care. Doxycycline was taken within 72 hours of the event and hair samples were obtained to determine doxycycline use. The study found that there was no significant reduction in STI cases over 12 months in the doxycycline-PEP group, and according to the hair analysis there was low doxycycline use suggesting low acceptance in the group assigned to receive it. In addition, there was a notable complete resistance to doxycycline in those testing positive for gonorrhoea. This highlights that although doxycycline-PEP has been used to improve outcomes in other groups, more research is needed with regard to protection against STIs, especially gonorrhoea, in cisgender women .

N Engl J Med 10.1056/NEJMoa2304007

Health-related quality of life and satisfaction associated with 3-year IUD use

Long-acting reversible contraception (LARC) use is increasing and contraceptive choice should be influenced by impact on quality of life. This study compared the levonorgestrel 13.5 mg intrauterine device (LNG 13.5-IUD) …